Akari appoints head of business development - oncology

US biotech Akari Therapeutics (Nasdaq: AKTX), which is developing novel payload antibody drug conjugates (ADCs), today announced the appointment of Mark Kubik as head of business development - oncology.

Mr Kubik is a well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates. He joins Akari from having most recently served as senior vice president, US and EU Business Development at I-MAB Biopharma where he was responsible for business development, alliance management and product / portfolio planning directed toward the  US and EU business and operating spheres.

Across his 25+ years career, Mr Kubik has established a successful track record of transformative deal creation and productive alliances including ADCs, empowered antibody therapies, and biologics for companies such as Seagen (now Pfizer), Abgenix (now Amgen), MacroGenics, and OncoImmune among others.